Panic Disorder and Response to Sertraline: The Effect of Previous Treatment with Benzodiazepines

  title={Panic Disorder and Response to Sertraline: The Effect of Previous Treatment with Benzodiazepines},
  author={Mark Hyman Rapaport and Mark H. Pollack and Cathryn M. Clary and Jack Mardekian and Robert Wolkow},
  journal={Journal of Clinical Psychopharmacology},
More than 50% of patients who seek psychiatric care for panic disorder have previously received prescriptions for a benzodiazepine (BZ). Research on the treatment of generalized anxiety suggests that a history of BZ exposure might decrease the efficacy and tolerability of treatment with a serotonergic anxiolytic. This study examines the effect of prior BZ treatment on the efficacy and tolerability of sertraline treatment for panic disorder. Data were pooled (N = 705) from four double-blind… 
Sertraline and alprazolam in the treatment of panic desorder.
Sertraline applied in fixed doses of 20mg/day and alprazolam in doses 1-1-5 mg/day significantly reduced the frequency of panic attacks in panic disorder patients, reduced symptoms of agoraphobia and anticipatory anxiety.
Treatment of panic disorder: recent developments and current status
  • V. Starcevic
  • Medicine, Psychology
    Expert review of neurotherapeutics
  • 2008
Improvements need to be made in the treatment of panic disorder, including simplified modes of delivery of cognitive–behavior therapy, optimal ways of combining medications with cognitive– behavior therapy, and minimizing the risk of recurrence after the cessation of treatment.
Effectiveness: the treatment of panic disorder in the real world
There needs to be even more attention to outcomes directly relevant to patients themselves, such as social functioning and much longer-term course in the future clinical studies.
Anxiety : Diagnosis and Treatment of Four Common Disorders
With 19.1 million (13.3%) of the adult population affected, anxiety disorders are the most common psychiatric disorders in the United States and primary care physicians will be called upon to diagnose anxiety disorders and treat patients who have them.


Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial.
Results support the safety and efficacy of sertraline for the short-term treatment of patients with panic disorder.
Sertraline in the treatment of panic disorder
Sertraline was effective and safe in reducing panic attacks and dry mouth and ejaculation failure (primarily ejaculation delay) were associated significantly with sERTraline.
Sertraline in the treatment of panic disorder: a double-blind multicenter trial.
Sertraline is an effective and well-tolerated treatment for patients with panic disorder and had significantly more improvement than placebo in scores on the Quality of Life Enjoyment and Satisfaction Questionnaire and Clinical Global Impression severity of illness and global improvement scales.
Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: results of a naturalistic follow-up study.
Patients with panic disorder or agoraphobia with panic attacks who had been placed on a regimen of tricyclic antidepressant treatment 1 to 4 years earlier reported at least moderate improvement during treatment; however, side effects were often difficult to tolerate, and 35% discontinued tricycleclic treatment on this account.
A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder.
Fluvoxamine was found to be an effective and well-tolerated treatment for panic using clinician- and patient-rated variables and cognitive therapy was not superior to fluvoxamine on any rating.
Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder.
The minimum dose demonstrated to be significantly superior to placebo was 40 mg/day, although some patients did respond at lower doses, and paroxetine is an effective and well-tolerated short-term treatment of panic disorder.
Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment.
Alprazolam was found to be effective and well tolerated in patients with agoraphobia with panic attacks and panic disorder and significantly more placebo recipients subsequently dropped out of the trial, primarily citing ineffectiveness of placebo as the reason.
Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder.
Endpoint analysis demonstrated a significant beneficial effect of both active treatments, but not placebo treatment, on the frequency of panic attacks, overall phobia ratings, and the extent of disability.
A naturalistic study of imipramine in panic disorder and agoraphobia.
There appears to be neither a clear threshold for response nor a therapeutic dose range for imipramine in the treatment of panic, and Doses should be adjusted individually and increased conservatively.
Lorazepam vs. alprazolam in the treatment of panic disorder.
Lorazepam appeared to be as effective as alprazolam in the acute treatment of panic disorder and was well-tolerated at a mean daily dose.